stockrowBioMarin Pharmaceutical Inc.
BMRN Healthcare Biotechnology
BioMarin Pharmaceutical Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 12.9% from fiscal 2024.
- Revenue
- +32.0%
- EPS
- −296.6%
- Free cash flow
- −52.3%
- Total debt
- +599.5%
Quarter to September 2026, against a year earlier
Follow BMRN
Alert me
BioMarin Pharmaceutical Inc. (BMRN) EPS (diluted)
BioMarin Pharmaceutical Inc.'s EPS (diluted) for fiscal 2025 was $1.80, down 18.6% from $2.21 in fiscal 2024. Over the twelve months to 30 September 2026 it was −$0.10. Over the past ten years it has ranged from −$3.81 (fiscal 2016) to $4.53 (fiscal 2020); the current reading is higher than 82% of that period. BioMarin Pharmaceutical Inc. ranks 64th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | $1.80 | (18.55%) |
| FY2024 | $2.21 | 154.02% |
| FY2023 | $0.87 | 16.00% |
| FY2022 | $0.75 | — |
| FY2021 | −$0.35 | — |
| FY2020 | $4.53 | — |
| FY2019 | −$0.13 | — |
| FY2018 | −$0.44 | — |
| FY2017 | −$0.67 | — |
| FY2016 | −$3.81 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Sep 2026 | −$0.63 | — |
| Jun 2026 | $0.23 | (57.41%) |
| Mar 2026 | $0.54 | — |
| Dec 2025 | −$0.24 | — |
| 43 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| TECH Bio-Techne Corp compare | $1.15 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| BMRN BioMarin Pharmaceutical Inc. | −$0.10 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
| PCVX Vaxcyte, Inc. compare | −$7.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on BMRN
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement